Hanmi Pharm: back-to-back technology export deals overshadow management dispute with strong core business
Predicted impact: Medium
Fabry drug export worth about 38% of revenue was already reported recently.
Hanmi Pharm한미약품
128940 · KOSPI · ₩128940 · 한미약품
₩388,500▲ ₩19,000 (5.14%)End-of-day · Oct 29, 2026 · End-of-day prices.
GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin
Predicted impact: Medium
$475m Fabry deal shared with Hanmi; already reported in recent days, and size is modest versus revenue.
[Stock of the Day] GC Genome, a Genetic Analysis Play, and Hanmi Pharm, Maker of a Domestic Obesity Drug, in Focus
Predicted impact: Low
Daily stock-pick mention with no company-specific facts or sizes given.
GC녹십자·한미약품, 파브리병 치료제 기술수출
High impactPredicted impact: High
Technology export up to $475M, about 38% of Hanmi Pharm's last year revenue (634.7B won deal).
[Stocks in Focus] Hanmi Pharm surges 8%+ on Fabry disease new drug tech export and obesity drug hopes
Predicted impact: Medium
Fabry technology export of about ₩635B already reported; this is a price move on known news.
[Market Live] KOSPI falls 3% as Samsung Electronics and SK Hynix weaken; Hanmi Pharm and security stocks strong
Predicted impact: Medium
Fabry drug tech export worth about ₩635B already reported; this is a market recap, not new.
GC Biopharma and Hanmi Pharm sign ₩634.7B technology export of Fabry disease drug to US's BioMarin, expanding K-pharma's reach
Predicted impact: Medium
₩634.7B license deal, about 38% of revenue, but already reported in earlier items this fortnight.
Hanmi Pharm and GC Biopharma license Fabry disease new drug for up to $475M in technology exports
Predicted impact: Medium
Up to $475M licensing deal, repeating the earlier Fabry drug export news.
GC Biopharma and Hanmi Pharm's jointly developed new drug licensed to US BioMarin
Predicted impact: Medium
Technology export up to $475M; about 640B won deal already reported earlier, roughly 39% of market value.
GC Biopharma and Hanmi Pharm export next-generation Fabry disease drug technology
Predicted impact: Medium
Next-gen Fabry technology export; likely the same deal as the ₩640B item.
GC Biopharma and Hanmi Pharm export Fabry disease drug candidate to US firm for ₩640B
High impactPredicted impact: High
₩640B tech export, about 13% of Hanmi's market value and 39% of revenue.
'4 Weeks, ₩130,000' K-Mounjaro Finally Launches; What About Hanmi Pharm Shares?
Predicted impact: Medium
Obesity drug launch was already reported in recent days; this is a follow-up with no new size data.
[Stock Spotlight] Hanmi Pharm Gains Over 3% as Domestically Developed Obesity Drug 'Efpeglenatide' Begins Prescriptions
Predicted impact: Low
Obesity drug prescription start already reported in the last 14 days.
K-Obesity Drug 'Efpeglenatide' Begins Prescriptions; Will Hanmi Pharm Spark a Rebound? [Stock+]
Predicted impact: Medium
Prescriptions of obesity drug begin; sales size unknown, earlier items only cited expectations, not launch.
Earnings shock and controversy over Corey investment review shake leadership of Hanmi Pharm CEO Hwang Sang-yeon
Predicted impact: Medium
Earnings shock and profit decline in Q3; leadership controversy adds some uncertainty to the stock.
[Hot Stock] Hanmi Pharm rises over 6% on news of ₩28.3B share cancellation
Predicted impact: Medium
Share cancellation of 28.3B won is about 0.6% of the 4.5T won market value; meaningful but smaller.
[Stock in Focus] Hanmi Pharm surges over 9% on pre-priced earnings concerns and obesity drug expectations
Predicted impact: Low
Share move reflects Q3 results already reported; earnings and obesity drug news were covered recently.
Hanmi Pharm: obesity drug sales and technology exports 'two-pronged'… earnings start to rebound
Predicted impact: Low
Q3 revenue up 4.2% and profit down; modest change already reported in the past 14 days.
Hanmi Pharm Q3 revenue ₩377.4B; operating and net profit down year on year
Predicted impact: Low
Q3 results already reported; profit decline was flagged in earlier items.
Hanmi Pharm Q3 revenue ₩377.4B, up 4.2% year on year
Predicted impact: Low
Also known as: Hanmi Pharm / 한미약품 / 128940 / KRX:128940
Source: KRX statistical information